ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 39

Role of Sialic Acid in the Aggressive Phenotype of RA FLS

Patricia Oliveira1, Brian Pedersen 1, Nissi Varki 2, Mark Fuster 1, Gary Firestein 3 and Monica Guma 4, 1UCSD, San Diego, CA, 2UCSD, San Diego, 3University of California, San Diego, San Diego, 4Department of Medicine, School of Medicine. University of California San Diego, La Jolla, United States

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: fibroblast-like synoviocytes, sialic acid and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Etiology & Pathogenesis Poster I

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: A comprehensive epigenomic characterization of rheumatoid arthritis (RA) fibroblast-like synoviocyte (FLS) has recently been described and can help to identify new critical pathways for RA pathogenesis. Two genes involved in sialylation, β-galactoside α2,3-sialyltransferase I (ST3Gal1) and β-galactoside α2,6-sialyltransferase I (ST6Gal1), were found to be significantly associated with changes in epigenetic marks between RA and osteoarthritis (OA) FLS, suggesting a role of this biological process in the aggressive phenotype of RA FLS. Here, we determined whether the amount of sialic acid (Sia) on FLS regulate its phenotype.

Methods: Methods: Sia expression in OA and RA synovial tissue was determined by using lectin immunofluorescence (IF).  Sialyltransferases (ST) gene expression and Sia expression after TNF or PDGF stimulation in RA FLS were analyzed by qPCR and by using lectin western blotting (WB),respectively.  Migrative (scratch assay) and invasive (matrigel assay) phenotype after PDGF stimulation were evaluated after treatment with neuraminidase (Neu) from Clostridium perfringens (25mU/ml for 60 minutes), which cleaves Sia from glycoconjugates, and with an endogenous neuraminidase inhibitor, N-Acetyl-2,3-dehydro-2-deoxyneuraminic acid (NADNA, 100uM). Metalloproteinases (MMP) and IL6 gene expression after TNF and PDGF stimulation was also analyzed after Neu treatment. For arthritis experiments, mice were injected with K/BxN sera on day 0. Lith-O-Asp (a sialyltransferase inhibitor, 3mg/kg) was injected every other day i.p. beginning on day 0 after serum administrationor starting at the peak of arthritis (from day 4). Clinical arthritis scores were serially assessed.

Results: Results:Maackia amurensis lectin I and II IF staining was higher in RA synovial lining.PDGF and TNF stimulation increased the expression of ST3Gal1 and ST6Gal1 and total amount of Sia in FLS. Neu treatment decreased the amount of Sia in FLS determined by WB and inhibited not only migration (Neu:26.94±5.4vs. vehicle:22.5±3.4; p< 0.001) and invasion (Neu:12.7±1.6 vs. vehicle:24.0±2.5; p< 0.001), but also the expression of MMP and IL-6 after TNF and PDGF stimulation.  Conversely, NADNA treatment increased the amount of Sia in RA FLS and enhanced both migration (vehicle:32.0±3.1vs. NADNA:16.5±5.0; p< 0.001)and invasion (vehicle:27.0±9.3vs. NADNA:39.5±13.6; p< 0.001). Finally, Lith-O-Asptreatment significantly decreased arthritis severity. Day 10 scores were 15.16±1.17 and 12.3±1.4(p=0.003) for vehicle and Lith-O-Asp-treated mice respectively, when mice were treated from day 0, and 15.2±1.2 and 11.3±2.2(p< 0.001) for vehicle and Lith-O-Asp -treated mice when mice were treated from day 4.

Conclusion: Conclusion: Sia are abundant on vertebrate glycoproteins and mediate a variety of biological phenomena, including migration and invasion. Our results suggest that in FLS, changes in the amounts of Sia likely mediated by changes in expression of ST3Gal1 and/or ST6Gal1, might be key regulator of FLS phenotype and contribute to joint destruction in RA. Modulation of Sia expression could act as disease modifying factor by directly modulating synoviocyte-mediated cartilage destruction.


Disclosure: P. Oliveira, None; B. Pedersen, None; N. Varki, None; M. Fuster, None; G. Firestein, Abbvie, 2, Janssen, 2; M. Guma, None.

To cite this abstract in AMA style:

Oliveira P, Pedersen B, Varki N, Fuster M, Firestein G, Guma M. Role of Sialic Acid in the Aggressive Phenotype of RA FLS [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/role-of-sialic-acid-in-the-aggressive-phenotype-of-ra-fls/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/role-of-sialic-acid-in-the-aggressive-phenotype-of-ra-fls/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology